CROCO- Crohn's Disease Cohort Study

  • Research type

    Research Study

  • Full title

    The CROCO Study- CROhn's disease COhort study

  • IRAS ID

    284239

  • Contact name

    Shaji Sebastian

  • Contact email

    shaji.sebastian4@nhs.net

  • Sponsor organisation

    Learning Health

  • Duration of Study in the UK

    7 years, 0 months, 1 days

  • Research summary

    Crohn's disease (CD) is a chronic inflammatory disease of unknown cause. Chronic inflammation predisposes to bowle complications including strictures (narrowing of the bowel), fistulas (communications between the bowel and other nearby organs) and abscesses. These are often managed by surgery where bowel is resected and refashioned. Over 50% of people with CD require surgery within 10 years of diagnosis due to complications or disease refractory to medical drugs.

    There are many markers to assess severity of inflammation such as cross-sectional imaging, endoscopy, blood and stool tests. These are used to assess response to therapy. Until recently there was no measure of progressive bowel damage. Measurement of bowel damage in CD is complex as the disease affects any part of the gut. Removal of small bowel segments at surgery compromised absorptive capability of the gut contributing to malnutrition, even though the residual bowel is normal. A new score called the Lemann Index was recently validated to capture progressive bowel damage including loss of bowel removed at surgery. This will allow an assessment of the impact of treatment on the natural history of the disease and not just on inflammation.

    The objective of the study is to understand and better characterise bowel damage progression in a prospective cohort of newly diagnosis CD patients.

    We propose to include patients diagnosed with CD over the last 12 months who are willing to have their data collected to measure the disease progression. The study will be based in 2 NHS hospitals in England and several centres across Europe.

    We propose to recruit patients over 2 years and follow them up over 5 years, There will be one additional MRI scan for the purpose of assessing Lemann Index . Patients will undergo routine clinical care and data will be collected for assessment of disease progress.

  • REC name

    South Central - Berkshire B Research Ethics Committee

  • REC reference

    22/SC/0035

  • Date of REC Opinion

    15 Feb 2022

  • REC opinion

    Favourable Opinion